TREM2 and dementia: AL002, a humanized monoclonal antibody, has demonstrated the capacity to elevate cell survival and proliferation through the activation of TREM2 signaling, thereby counteracting dementia potentially arising from compromised TREM2 functionality, while simultaneously invigorating microglial activity.